Study the Role of Phenobarbitone in the treatment Of Neonatal Hyperbilirubinemia in Low Birth Weight Neonates AN Open Labeled Randomised Control Trial

Aditi Lingayat; Patil PS; Rahul Kamble

Volume : IV, Issue : VIII, August - 2015

Study the Role of Phenobarbitone in the treatment Of Neonatal Hyperbilirubinemia in Low Birth Weight Neonates AN Open Labeled Randomised Control Trial

Aditi Lingayat, Patil Ps, Rahul Kamble

Abstract :

Objective: To study the role of phenobarbitone in the treatment of neonatal hyperbilirubinemia in low birth weight neonate and the adverse effects of phenobarbitone. Methods: All the low birth weight neonates admitted in NICU over a period of 2yr from November 2010 to November 2012 were enrolled in the study. 80 cases were randomized into 40 cases and 40 controls. Neonates fulfilling inclusion criteria randomized according to computer generated random number table, oral phenobarbitone 10mg/kg loding dose at the start of therapy followed by 5mg/kg/day in two divided doses for subsequent 4days along with phototherapy was given to A Group; only phototherapy for B Group. Serum bilirubin will be done on admission then every 12hrly for 3 days and every 24 hrly for next 2 days. Results: The baseline characteristics were similar in two groups. There was no significant difference in mean peak serum bilirubin levels and no significant difference in reduction of serum bilirubin levels estimated over 5 days after use of phenobarbitone in these neonates. Phenobarbitone will not decrease the duration of phototherapy required and exchange transfusion requirement in both of these group. The only adverse noted with phenobarbitone is drowsiness. Conclusions: Phenobarbitone has no role in treatment of neonatal hyperbilirubinemia.